# Docetaxel and Epirubicin in Advanced Gastric Cancer

> **NCT00375999** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 34 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Docetaxel and epirubicin

## Key facts

- **NCT ID:** NCT00375999
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375999, "Docetaxel and Epirubicin in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00375999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*